Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.